Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sosei Group ( (JP:4565) ) has shared an update.
Nxera Pharma reported significant achievements in 2024, including the successful launch of PIVLAZ™ and QUVIVIQ™ in Japan, contributing to substantial revenue growth. The company is advancing its clinical pipeline with late-stage trials and forging strategic partnerships, positioning it as a leader in the biopharmaceutical sector. The expansion into South Korea and collaborations with tech companies highlight Nxera’s commitment to innovation and market expansion.
More about Sosei Group
Nxera Pharma is a technology-driven biopharmaceutical company focused on developing and bringing new medicines to patients in Japan and globally. The company operates within the biopharmaceutical industry, with a focus on neurology, neuropsychiatry, metabolic diseases, immunology, and inflammation. Key products include PIVLAZ™ and QUVIVIQ™, and the company is expanding its market presence in Asia.
YTD Price Performance: -1.67%
Average Trading Volume: 614
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $585.8M
See more insights into 4565 stock on TipRanks’ Stock Analysis page.